Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIPER-OCTA: OctaplasLG for Endothelial Integrity in Aortic Dissection
NCT02253082Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Nov 2014
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of octaplas lg in thoracic aortic dissection (TAD), sponsored by Rigshospitalet. Started Nov 2014; status: completed.
02
Drugs
octaplas lg
03
Conditions
thoracic aortic dissection (TAD)
Beyond the preview
Go deeper on NCT02253082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253082.